



FOR IMMEDIATE RELEASE

Contact:

Risa Goldman Burgess or Ted Smith
Schwartz Communications, Inc.
781-684-0770
codagenomics@schwartz-pr.com

CODA GENOMICS NAMES STEPHEN PICATAGGIO TO CHIEF SCIENTIFIC OFFICER

Laguna Hills Synthetic Biology Company Expands Executive Team to Manage Increased Demand for Technology from Industrial Biotechnology and Life Sciences Customers

LAGUNA HILLS, Calif.—Oct. 27, 2008— CODA Genomics, a synthetic biology company focused on industrial biotechnology and life sciences markets, today announced the appointment of Stephen Picataggio, Ph.D. to the position of Chief Scientific Officer.

Dr. Picataggio brings more than 30 years experience in the metabolic engineering of industrial microorganisms and the development of fermentation processes for the production of fuels and chemicals. He joins at a time when bioindustrial customers are increasing demand for the CODA technology platform.

“We are excited to have Steve join the CODA management team,” said Bill Radany, CEO, CODA Genomics. “With Steve on board, and demand for CODA’s technology on the rise, we will be able to fully capitalize and execute on this exciting, new strategic business direction for the company. His extensive knowledge and relevant industry experience will play a critical role in our continued growth and expansion as a bioindustrial and biofuels technology provider.”

“CODA’s technology platform has enormous potential in the industrial biotechnology sector and beyond,” said Dr. Picataggio. “I’m looking forward to working with CODA’s management team to establish a scientific roadmap and execute a commercialization strategy to satisfy increasing demand for our technology and support services.”

Prior to joining CODA, Dr. Picataggio served as Vice President of Metabolic Engineering at Synthetic Genomics, Inc. and held various leadership positions at Dupont Central Research & Development, the National Renewable Energy Laboratory and Cognis, Inc., formerly Henkel Research Corporation. He is the author of more than 15 academic papers and an inventor on more than 45 issued and pending patents.

He earned a Bachelor of Science degree in Bacteriology and Public Health from Wagner College and graduated *magna cum laude*. He received his Ph.D. in microbiology from Rutgers University.

About CODA Genomics, Inc.

Founded in 2005, CODA Genomics, Inc. is a privately-held synthetic biology company focused on solving complex biology problems via its proprietary technologies that enable the creation of novel genes, proteins and organisms. Investors in CODA include OVP Venture Partners, Monitor Ventures, Tech Coast Angels and Life Science Angels. For more information on CODA, visit www.codagenomics.com.

###